The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy

Virology

Volumn 435, Issue 1, 2013, Pages 102-109

  Christ, Frauke ^a   Debyser, Zeger ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Co factor; Drug discovery; HIV; INSTI; Integrase; LEDGF p75; LEDGINs; Peptides; Structure based design

Indexed keywords

2 (TERT BUTOXY) 2 SUBSTITUTED ACETIC ACID DERIVATIVE; ANTIRETROVIRUS AGENT; CX 014442; CX 04238; CX 05045; DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; LENS EPITHELIUM DERIVED GROWTH FACTOR; NEW DRUG; PROTEIN P75; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; VIRUS REPLICATION;

ACETATES; DRUG DISCOVERY; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84870670336     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.09.033     Document Type: Review

References (71)

1. Al-Mawsawi L.Q., Christ F., Dayam R., Debyser Z., Neamati N. Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis. FEBS Lett. 2008, 582(10):1425-1430.
2. Aravind L., Landsman D. AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res. 1998, 26(19):4413-4421.
3. Baldanti F., Paolucci S., Gulminetti R., Brandolini M., Barbarini G., Maserati R. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J. Med. Virol. 2010, 82(1):116-122.
4. Bartholomeeusen K., De Rijck J., Busschots K., Desender L., Gijsbers R., Emiliani S., Benarous R., Debyser Z., Christ F. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75. J. Mol. Biol. 2007, 372(2):407-421.
5. Bartholomeeusen K., Gijsbers R., Christ F., Hendrix J., Rain J.C., Emiliani S., Benarous R., Debyser Z., De Rijck J. Lens Epithelium Derived Growth Factor/p75 interacts with the transposase derived DDE domain of pogZ. J. Biol. Chem 2009.
6. Busschots K., Voet A., De Maeyer M., Rain J.C., Emiliani S., Benarous R., Desender L., Debyser Z., Christ F. Identification of the LEDGF/p75 binding site in HIV-1 integrase. J. Mol. Biol. 2007, 365(5):1480-1492.
7. Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., De Clercq E., Debyser Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 2003, 278(1):372-381.
8. Cherepanov P., Devroe E., Silver P.A., Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J. Biol. Chem. 2004, 279(47):48883-48892.
9. Cherepanov P., Ambrosio A.L., Rahman S., Ellenberger T., Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Nat. Acad. Sci. USA 2005, 102(48):17308-17313.
10. Cherepanov P., Sun Z.Y., Rahman S., Maertens G., Wagner G., Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat. Struct. Mol. Biol. 2005, 12(6):526-532.
11. Christ F., Shaw S., Demeulemeester J., Desimmie B.A., Marchand A., Butler S., Smets W., Chaltin P., Westby M., Debyser Z., Pickford C. Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization. Antimicrob. Agents Chemother 2012.
12. Christ F., Voet A., Marchand A., Nicolet S., Desimmie B.A., Marchand D., Bardiot D., Van der Veken N.J., Van Remoortel B., Strelkov S.V., De Maeyer M., Chaltin P., Debyser Z. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 2010, 6(6):442-448.
13. Ciuffi A., Llano M., Poeschla E., Hoffmann C., Leipzig J., Shinn P., Ecker J.R., Bushman F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 2005, 11(12):1287-1289.
14. De Luca L., Barreca M.L., Ferro S., Iraci N., Michiels M., Christ F., Debyser Z., Witvrouw M., Chimirri A. A refined pharmacophore model for HIV-1 integrase inhibitors: optimization of potency in the 1H-benzylindole series. Bioorg. Med. Chem. Lett. 2008, 18(9):2891-2895.
15. De Luca L., Barreca M.L., Ferro S., Christ F., Iraci N., Gitto R., Monforte A.M., Debyser Z., Chimirri A. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 2009, 4(8):1311-1316.
16. De Luca L., De Grazia S., Ferro S., Gitto R., Christ F., Debyser Z., Chimirri A. HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation. Eur. J. Med. Chem. 2010, 46(2):756-764.
17. De Luca L., Gitto R., Christ F., Ferro S., De Grazia S., Morreale F., Debyser Z., Chimirri A. 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. Antiviral Res. 2011, 92(1):102-107.
18. De Rijck J., Vandekerckhove L., Gijsbers R., Hombrouck A., Hendrix J., Vercammen J., Engelborghs Y., Christ F., Debyser Z. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J. Virol. 2006, 80(23):11498-11509.
19. Desimmie B.A., Humbert M., Lescrinier E., Hendrix J., Vets S., Gijsbers R., Ruprecht R.M., Dietrich U., Debyser Z., Christ F. Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. Mol. Ther 2012.
20. Dietz F., Franken S., Yoshida K., Nakamura H., Kappler J., Gieselmann V. The family of hepatoma-derived growth factor proteins: characterization of a new member HRP-4 and classification of its subfamilies. Biochem. J. 2002, 366(Pt. 2):491-500.
21. Du L., Zhao Y., Chen J., Yang L., Zheng Y., Tang Y., Shen X., Jiang H. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem. Biophys. Res. Commun. 2008, 375(1):139-144.
22. Emiliani S., Mousnier A., Busschots K., Maroun M., Van Maele B., Tempe D., Vandekerckhove L., Moisant F., Ben-Slama L., Witvrouw M., Christ F., Rain J.C., Dargemont C., Debyser Z., Benarous R. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 2005, 280(27):25517-25523.
23. Espeseth A.S., Felock P., Wolfe A., Witmer M., Grobler J., Anthony N., Egbertson M., Melamed J.Y., Young S., Hamill T., Cole J.L., Hazuda D.J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Nat. Acad. Sci. USA 2000, 97(21):11244-11249.
24. Fan X., Zhang F.H., Al-Safi R.I., Zeng L.F., Shabaik Y., Debnath B., Sanchez T.W., Odde S., Neamati N., Long Y.Q. Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. Bioorg. Med. Chem. 2011, 19(16):4935-4952.
25. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47(7):1739-1749.
26. Ganapathy V., Daniels T., Casiano C.A. LEDGF/p75: a novel nuclear autoantigen at the crossroads of cell survival and apoptosis. Autoimmun. Rev. 2003, 2(5):290-297.
27. Garrido C., Soriano V., Geretti A.M., Zahonero N., Garcia S., Booth C., Gutierrez F., Viciana I., de Mendoza C. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients-impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 2011, 90(3):164-167.
28. Ge H., Si Y., Roeder R.G. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J. 1998, 17(22):6723-6729.
29. Gijsbers R., Vets S., De Rijck J., Ocwieja K.E., Ronen K., Malani N., Bushman F.D., Debyser Z. Role of the PWWP domain of lens epithelium-derived growth factor (LEDGF)/p75 cofactor in lentiviral integration targeting. J. Biol. Chem. 2011, 286(48):41812-41825.
30. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464(7286):232-236.
31. Hayouka Z., Hurevich M., Levin A., Benyamini H., Iosub A., Maes M., Shalev D.E., Loyter A., Gilon C., Friedler A. Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. Bioorg. Med. Chem. 2010, 18(23):8388-8395.
32. Hayouka Z., Levin A., Maes M., Hadas E., Shalev D.E., Volsky D.J., Loyter A., Friedler A. Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. Biochem. Biophys. Res. Commun. 2010, 394(2):260-265.
33. Hayouka Z., Rosenbluh J., Levin A., Loya S., Lebendiker M., Veprintsev D., Kotler M., Hizi A., Loyter A., Friedler A. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc. Nat. Acad. Sci. USA 2007, 104(20):8316-8321.
34. Hendrix J., Gijsbers R., De Rijck J., Voet A., Hotta J., McNeely M., Hofkens J., Debyser Z., Engelborghs Y. The transcriptional co-activator LEDGF/p75 displays a dynamic scan-and-lock mechanism for chromatin tethering. Nucleic Acids Res. 2011, 39(4):1310-1325.
35. Hombrouck A., De Rijck J., Hendrix J., Vandekerckhove L., Voet A., De Maeyer M., Witvrouw M., Engelborghs Y., Christ F., Gijsbers R., Debyser Z. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog. 2007, 3(3):e47.
36. Hombrouck A., Hantson A., van Remoortel B., Michiels M., Vercammen J., Rhodes D., Tetz V., Engelborghs Y., Christ F., Debyser Z., Witvrouw M. Selection of human immunodeficiency virus type 1 resistance against the pyranodipyrimidine V-165 points to a multimodal mechanism of action. J. Antimicrob. Chemother. 2007, 59(6):1084-1095.
37. Hou Y., McGuinness D.E., Prongay A.J., Feld B., Ingravallo P., Ogert R.A., Lunn C.A., Howe J.A. Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J. Biomol. Screen. 2008, 13(5):406-414.
38. Hu G., Li X., Sun X., Lu W., Liu G., Huang J., Shen X., Tang Y. Identification of old drugs as potential inhibitors of HIV-1 integrase-human LEDGF/p75 interaction via molecular docking. J. Mol. Model 2012.
39. Izumoto Y., Kuroda T., Harada H., Kishimoto T., Nakamura H. Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus. Biochem. Biophys. Res. Commun. 1997, 238(1):26-32.
40. Kessl J.J., Jena N., Koh Y., Taskent-Sezgin H., Slaughter A., Feng L., de Silva S., Wu L., Le Grice S.F., Engelman A., Fuchs J.R., Kvaratskhelia M. A multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J. Biol. Chem 2012.
41. Kessl J.J., Li M., Ignatov M., Shkriabai N., Eidahl J.O., Feng L., Musier-Forsyth K., Craigie R., Kvaratskhelia M. FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75. Nucleic Acids Res. 2011, 39(20):9009-9022.
42. Llano M., Delgado S., Vanegas M., Poeschla E.M. Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase. J. Biol. Chem. 2004, 279(53):55570-55577.
43. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., Teo W., Poeschla E.M. An essential role for LEDGF/p75 in HIV integration. Science 2006, 314(5798):461-464.
44. Llano M., Vanegas M., Hutchins N., Thompson D., Delgado S., Poeschla E.M. Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J. Mol. Biol. 2006, 360(4):760-773.
45. Maertens G., Cherepanov P., Pluymers W., Busschots K., De Clercq E., Debyser Z., Engelborghs Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 2003, 278(35):33528-33539.
46. Maertens G.N., Cherepanov P., Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J. Cell Sci. 2006, 119(Pt. 12):2563-2571.
47. Maignan S., Guilloteau J.P., Zhou-Liu Q., Clement-Mella C., Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282(2):359-368.
48. Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., Tchertanov L., Peytavin G., Reynes J., Mouscadet J.F., Katlama C., Calvez V., Marcelin A.G. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 2008, 52(4):1351-1358.
49. Marshall H.M., Ronen K., Berry C., Llano M., Sutherland H., Saenz D., Bickmore W., Poeschla E., Bushman F.D. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PloS One 2007, 2(12):e1340.
50. McNeely M., Hendrix J., Busschots K., Boons E., Deleersnijder A., Gerard M., Christ F., Debyser Z. In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75. J. Mol. Biol. 2011, 410(5):811-830.
51. Min S., Sloan L., Dejesus E., Hawkins T., McCurdy L., Song I., Stroder R., Chen S., Underwood M., Fujiwara T., Piscitelli S., Lalezari J. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011, 25(14):1737-1745.
52. Molteni V., Greenwald J., Rhodes D., Hwang Y., Kwiatkowski W., Bushman F.D., Siegel J.S., Choe S. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta Crystallogr. Sect. D.(:) Biol. Crystallogr. 2001, 57(Pt. 4):536-544.
53. Murray J.M., Emery S., Kelleher A.D., Law M., Chen J., Hazuda D.J., Nguyen B.Y., Teppler H., Cooper D.A. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007, 21(17):2315-2321.
54. Nishizawa Y., Usukura J., Singh D.P., Chylack L.T., Shinohara T. Spatial and temporal dynamics of two alternatively spliced regulatory factors, lens epithelium-derived growth factor (ledgf/p75) and p52, in the nucleus. Cell Tissue Res. 2001, 305(1):107-114.
55. Peat T.S., Rhodes D.I., Vandegraaff N., Le G., Smith J.A., Clark L.J., Jones E.D., Coates J.A., Thienthong N., Newman J., Dolezal O., Mulder R., Ryan J.H., Savage G.P., Francis C.L., Deadman J.J. Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design. PloS One 2012, 7(7):e40147.
56. Rhodes D.I., Peat T.S., Vandegraaff N., Jeevarajah D., Newman J., Martyn J., Coates J.A., Ede N.J., Rea P., Deadman J.J. Crystal structures of novel allosteric peptide inhibitors of HIV integrase identify new interactions at the LEDGF binding site. ChemBioChem 2011, 12(15):2311-2315.
57. Schrijvers R., De Rijck J., Demeulemeester J., Adachi N., Vets S., Ronen K., Christ F., Bushman F.D., Debyser Z., Gijsbers R. LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog. 2012, 8(3):e1002558.
58. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., Watanabe Y., Ohata Y., Doi S., Sato M., Kano M., Ikeda S., Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82(2):764-774.
59. Shun M.C., Daigle J.E., Vandegraaff N., Engelman A. Wild-type levels of human immunodeficiency virus type 1 infectivity in the absence of cellular emerin protein. J. Virol. 2007, 81(1):166-172.
60. Shun M.C., Raghavendra N.K., Vandegraaff N., Daigle J.E., Hughes S., Kellam P., Cherepanov P., Engelman A. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 2007, 21(14):1767-1778.
61. Singh D.P., Kimura A., Chylack L.T., Shinohara T. Lens epithelium-derived growth factor (LEDGF/p75) and p52 are derived from a single gene by alternative splicing. Gene 2000, 242(1-2):265-273.
62. Singh D.P., Ohguro N., Kikuchi T., Sueno T., Reddy V.N., Yuge K., Chylack L.T., Shinohara T. Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. Biochem. Biophys. Res. Commun. 2000, 267(1):373-381.
63. Stec I., Nagl S.B., van Ommen G.J., den Dunnen J.T. The PWWP domain: a potential protein-protein interaction domain in nuclear proteins influencing differentiation?. FEBS Lett. 2000, 473(1):1-5.
64. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., Jones P., Kinzel O., Laufer R., Monteagudo E., Muraglia E., Nizi E., Orvieto F., Pace P., Pescatore G., Scarpelli R., Stillmock K., Witmer M.V., Rowley M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51(18):5843-5855.
65. Tsiang M., Jones G.S., Niedziela-Majka A., Kan E., Lansdon E.B., Huang W., Hung M., Samuel D., Novikov N., Xu Y., Mitchell M., Guo H., Babaoglu K., Liu X., Geleziunas R., Sakowicz R. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J. Biol. Chem 2012.
66. Tsutsui K.M., Sano K., Hosoya O., Miyamoto T., Tsutsui K. Nuclear protein LEDGF/p75 recognizes supercoiled DNA by a novel DNA-binding domain. Nucleic Acids Res. 2011, 39(12):5067-5081.
67. Turlure F., Maertens G., Rahman S., Cherepanov P., Engelman A. A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res. 2006, 34(5):1663-1675.
68. Van Maele B., Busschots K., Vandekerckhove L., Christ F., Debyser Z. Cellular co-factors of HIV-1 integration. Trends Biochem. Sci 2006.
69. Vandekerckhove L., Christ F., Van Maele B., De Rijck J., Gijsbers R., Van den Haute C., Witvrouw M., Debyser Z. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J. Virol. 2006, 80(4):1886-1896.
70. Yokoyama A., Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008, 14(1):36-46.
71. Zolopa A.R., Berger D.S., Lampiris H., Zhong L., Chuck S.L., Enejosa J.V., Kearney B.P., Cheng A.K. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J. Infect. Dis. 2010, 201(6):814-822.